<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02498522</url>
  </required_header>
  <id_info>
    <org_study_id>Metformin in pregnancy</org_study_id>
    <nct_id>NCT02498522</nct_id>
  </id_info>
  <brief_title>Effect of Metformin on Early Pregnancy Loss in Pregnant Women With Polycystic Ovarian Syndrome</brief_title>
  <acronym>MIP</acronym>
  <official_title>Effect of Metformin on Early Pregnancy Loss in Pregnant Women With Polycystic Ovarian Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this work is to study the effect of metformin use for reducing early pregnancy
      loss in pregnant patients with Polycystic ovary syndrome (PCOS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of
      reproductive age. PCOS produces symptoms in approximately 5 to 10% of women of reproductive
      age (12-45 years old) and is thought to be one of the leading causes of the female
      subfertility

        -  The aim of this work is to study the effect of metformin use for reducing early
           pregnancy loss in pregnant patients with PCOS

        -  Research question:

      In pregnant women with PCOS, does metformin use decreases the rate of early pregnancy loss?

      -Research hypothesis: In Pregnant women with PCOS, metformin may reduce the rate of early
      pregnancy loss.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Miscarriage Rate</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">166</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>metformin arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>83 patients will continue metformin until end of 1st trimester (14 weeks gestation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>83 patients will stop metformin at diagnosis of pregnancy ( 5-6 weeks gestation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>83 patients will continue metformin until end of 1st trimester</description>
    <arm_group_label>metformin arm</arm_group_label>
    <arm_group_label>control arm</arm_group_label>
    <other_name>cidophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age : 25 - 35.

          -  Pregnant patients in their 1st trimester with history of infertility due to PCOS
             confirmed by at least 2 of the following criteria ( Rotterdam Criteria )

               -  At least twelve small follicles 2-9 mm in at least one ovary; diagnosed by ultra
                  sound examination.

               -  Symptoms or biochemical evidence of hyperandrogenism; diagnosed by examination
                  and laboratory investigations.

               -  Anovulation or oligo-ovulation with fewer than nine menstrual periods every 12
                  months : diagnosed by thorough history taking.

          -  Non diabetic patients who received metformin along with other ovulation-inducing drugs
             prior to pregnancy.

        Exclusion Criteria:

          -  patients with other causes of infertility other than PCOS

          -  contraindications to metformin : liver impairment , renal failure.

          -  Patients with PCOS who didn't receive Metformin with drugs of induction of ovulation
             before pregnancy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed M kotb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine, Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <state>Al Qahirah</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2015</study_first_submitted>
  <study_first_submitted_qc>July 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2015</study_first_posted>
  <results_first_submitted>March 28, 2016</results_first_submitted>
  <results_first_submitted_qc>April 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 19, 2016</results_first_posted>
  <last_update_submitted>April 13, 2016</last_update_submitted>
  <last_update_submitted_qc>April 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Islam Dabbous</investigator_full_name>
    <investigator_title>doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Abortion, Spontaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metformin Arm</title>
          <description>83 patients will continue metformin until end of 1st trimester (14 weeks gestation)
Metformin: 83 patients will continue metformin until end of 1st trimester</description>
        </group>
        <group group_id="P2">
          <title>Control Arm</title>
          <description>83 patients will stop metformin at diagnosis of pregnancy ( 5-6 weeks gestation)
Metformin: 83 patients will continue metformin until end of 1st trimester</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin Arm</title>
          <description>83 patients will continue metformin until end of 1st trimester (14 weeks gestation)
Metformin: 83 patients will continue metformin until end of 1st trimester</description>
        </group>
        <group group_id="B2">
          <title>Control Arm</title>
          <description>83 patients will stop metformin at diagnosis of pregnancy ( 5-6 weeks gestation)
Metformin: 83 patients will continue metformin until end of 1st trimester</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83"/>
            <count group_id="B2" value="83"/>
            <count group_id="B3" value="166"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.2" spread="1.6"/>
                    <measurement group_id="B2" value="30.1" spread="1.9"/>
                    <measurement group_id="B3" value="30.1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Egypt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Miscarriage Rate</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin Arm</title>
            <description>83 patients will continue metformin until end of 1st trimester (14 weeks gestation)
Metformin: 83 patients will continue metformin until end of 1st trimester</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>83 patients will stop metformin at diagnosis of pregnancy ( 5-6 weeks gestation)
Metformin: 83 patients will continue metformin until end of 1st trimester</description>
          </group>
        </group_list>
        <measure>
          <title>Miscarriage Rate</title>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="4.1" upper_limit="17.5"/>
                    <measurement group_id="O2" value="35" lower_limit="31.6" upper_limit="52.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Metformin Arm</title>
          <description>83 patients will continue metformin until end of 1st trimester (14 weeks gestation)
Metformin: 83 patients will continue metformin until end of 1st trimester</description>
        </group>
        <group group_id="E2">
          <title>Control Arm</title>
          <description>83 patients will stop metformin at diagnosis of pregnancy ( 5-6 weeks gestation)
Metformin: 83 patients will continue metformin until end of 1st trimester</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="83"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ahmed kotb</name_or_title>
      <organization>AinShamsU</organization>
      <phone>1008681999 ext +20</phone>
      <email>ahmedmkotp@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

